Results 11 to 20 of about 20,052 (248)

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. [PDF]

, 2018
Altres ajuts: C.M. is supported by the Deutsche Forschungsgemeinschaft (DFG; SFB 894, TRR-219, and Ma 2528/7-1), the German Federal Ministry of Education and Science (BMBF; 01EO1504) and the Corona foundation. J.B.
12, 19, 29, 31 32, 33, 6, Alessandra Dei Cas18, Alexander R. Lyon24, and Stephane Heymans, Antoni Bayes-Genis11, Arantxa Gonza´lez20, Bart Staels30, Christoph Maack1, ChristophWanner35, Dimitrios Farmakis36, Dirk Brutsaert13, Francesco Cosentino16, Frank R. Heinzel4, Frank Ruschitzka37, Gerasimos Filippatos36, Gilles De Keulenaer17, Giuseppe Rosano28, Graham Rena26, Guido Iaccarino, Heiko Bugger14, Heinrich Taegtmeyer9, Ida Gjervold Lunde23, Jean-Sebastien Hulot5, Johann Bauersachs10, Johannes Backs3, Kieran Clarke15, LindaW. van Laake34, Martin Huelsmann21, Michael Lehrke2, Niels P. Riksen27, Nikolaus Marx2, Patrick Rossignol8, Petar Seferovic38, Piero Pollesello25, Rudolf A. de Boer39, Walter J. Paulus7   +40 more
core   +20 more sources

Safety of Semaglutide

Frontiers in Endocrinology, 2021
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation.
Mark M. Smits, Daniël H. Van Raalte
doaj   +1 more source

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis

Frontiers in Pharmacology, 2021
Background: Cardio-renal profiles are available from cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).Methods: A comprehensive systematic review of Embase, Medline, Web of Knowledge, and CENTRAL databases was ...
Chuanjun Zhuo, Chuanjun Zhuo, Chuanjun Zhuo, Chuanjun Zhuo, Chongguang Lin, Chunhua Zhou, Xiangyang Gao, Hailin Shao, Tao Fang, Hongjun Tian, Li Ding, Ming Liu   +11 more
doaj   +1 more source

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Cardiovascular Diabetology, 2020
Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations.
Mansoor Husain, Stephen C. Bain, Anders Gaarsdal Holst, Thomas Mark, Søren Rasmussen, Ildiko Lingvay   +5 more
doaj   +1 more source

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes [PDF]

, 2016
Background: Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk.
Bain, Stephen C., Baldassarre, Maria Pompea Antonia, Consoli, Agostino, Eliaschewitz, Freddy G., Hansen, Oluf, Holst, Anders G., Jodar, Esteban, Leiter, Lawrence A., Lingvay, Ildiko, Marso, Steven P, Pettersson, Jonas, Rosenstock, Julio, Seufert, Jochen, Vilsboll, Tina, Warren, Mark L., Woo, Vincent   +15 more
core   +2 more sources

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review

Clinical Epidemiology, 2022
Zeyu Xie, Sensen Yang, Weishang Deng, Jinjian Li, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Yang S, Deng W, Li J, Chen J
doaj  

Some doubts about the mantra on the deleterious cardiovascular effects of sulfonylureas [PDF]

, 2017
[No abstract ...
Prudente, Sabrina, Trischitta, Vincenzo
core   +1 more source

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]

, 2018
Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V., Goodwill, Adam, Green, Mark A., Hamilton, LaTonya, Hutchins, Gary D., Mather, Kieren J., Mathias, Carla, Patel, Niral A., Territo, Wendy, Tune, Johnathan D.   +9 more
core   +1 more source

Guidelines for type 2 diabetes: keeping a finger on the pulse [PDF]

, 2017
Cardiovascular disease remains the biggest cause of morbidity and mortality in patients with type 2 diabetes.1 Individual drugs from two classes of glucose-lowering agents, glucagon-like peptide-1 (GLP-1)receptor agonists and sodium-glucose cotransporter-
Barnett, Anthony H., Halcox, Julian, O'Hare, J. Paul   +2 more
core   +1 more source